Astal Laboratories Ltd (ASTALLTD) is currently trading at 63.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Astal Laboratories Limited is a listed manufacturer and trader of pharmaceutical intermediates and bulk drugs, having repositioned its core activity to APIs and key starting materials after a change in control and name change; it is now a subsidiary of Aceso Research Labs LLP and reports consolidated results including a material wholly owned subsidiary. Recent financials show consolidated revenue of Rs. 100.94 crore and consolidated profit after tax of Rs. 9.42 crore for the reported quarter, while standalone revenue was Rs. 39.51 crore with PAT of Rs. 3.71 crore; consolidated EPS (basic) was reported at Rs. 2.188, indicating meaningful contribution from the subsidiary to group profitability. The company completed a strategic pivot into manufacturing and trading of active pharmaceutical ingredients starting FY2025, after a SEBI‑guided takeover in 2022 and a corporate name change in 2024, signalling management’s clear shift toward API production to capture growing global demand for pharmaceutical ingredients. Audit governance notes: the quarterly standalone and consolidated financial results were reviewed by auditors and approved by the Board on 14 August 2026; the consolidated numbers explicitly include Sriven Pharmachem’s quarterly revenue of Rs. 61.53 crore and profit contributions, highlighting how consolidation materially increased reported group scale.

Over the past 52 weeks, Astal Laboratories Ltd has traded between a low of ₹60.45 and a high of ₹101.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Astal Laboratories Ltd has a market capitalization of approximately 279.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Astal Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.59 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 279.48 Cr, Astal Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Astal Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Astal Laboratories Ltd is 12.59. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.